GREENWICH LIFESCIENCES INC

Greenwich Lifesciences’ battle to bring Texas‑focused cancer therapies to market amid sharp stock declines and a negative P/E, highlighting biotech risks and investor caution.

Greenwich Lifesciences faces mounting losses as it pushes breast‑cancer immunotherapy forward, relying on equity sales to stay afloat while seeking new funding for its Phase III trials.

Greenwich Lifesciences Q2 2026 results: $9.6 M loss amid R&D push, $8.9 M cash, Phase III breast‑cancer trial funding, Nasdaq stock outlook.

Greenwich Lifesciences revamps FLAMINGO‑01 breast‑cancer vaccine trial—broader enrollment, new endpoints, and digital tracking—while shares drop, highlighting market reaction to design changes.

Greenwich Lifesciences expands FLAMINGO‑01 Europe enrollment, gaining EMA approval to combine HLA‑A02:01 and HLA‑A24:02, boosting oncology trial power and investor appeal.

Explore Greenwich Lifesciences’ latest stock insights, market performance, and cutting‑edge cancer research breakthroughs – discover why investors are watching this biotech firm closely.

Greenwich Lifesciences secures FDA approval for its commercial GP2 lot, clearing a key milestone toward GLSI‑100’s BLA filing and faster breast‑cancer prevention access.

Greenwich Lifesciences completes enrollment of 250 non‑HLA‑A*02 patients in its FLAMINGO‑01 Phase‑III trial for GLSI‑100, a breast‑cancer recurrence immunotherapy.

Greenwich Lifesciences, Inc. is a biotech company dedicated to developing cancer treatments, operating under the Nasdaq stock exchange and committed to improving patient care despite financial challenges.

Greenwich Lifesciences, a biotechnology company, is dedicated to developing cancer treatments, with a focus on serving Texas patients, despite facing financial challenges.